Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis.

Abstract

To examine the effect of switching from a prostanoid FP receptor agonists to EP2 receptor agonist (omidenepag isopropyl) on the deepening of the upper eyelid sulcus (DUES) and intraocular pressure (IOP) in Japanese glaucoma patients over 3months post treatment. Prospective observational study. Patients with glaucoma who received FP receptor agonists treatment and had complained of DUES-related reduction in quality of life were included. Their FP receptor agonists was switched to omidenepag isopropyl without a drug holiday. At baseline and 1 and 3months post-switch, photographs were taken and the changes in DUES were assessed by three independent observers. IOP and adverse events were also assessed. The study included 23 eyes of 23 patients (6 men, 17 women; average age, 60.6years). After switching, DUES improved in 12 eyes at 1month and in 16 eyes at 3months; eyes in the remaining patients showed no worsening of the condition. The mean IOP before switching was 15.3 ± 3.3mmHg (95% confidence interval 13.9-16.7mmHg). Following the switch, the mean IOP values were 15.6 ± 3.3mmHg (14.1-17.0mmHg) at 1month and 15.5 ± 3.3mmHg (14.1-16.9mmHg) at 3months (P = 1.0 at 1month, P = 1.0 at 3months; both adjusted by Bonferroni correction). No adverse effects were observed. Omidenepag isopropyl improved DUES while maintaining IOP in over 70% of Japanese patients with glaucoma who exhibited DUES caused by FP receptor agonists; the improvement was observed within 3months after switching from FP receptor agonists.